Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation
- PMID: 31673695
- PMCID: PMC7127130
- DOI: 10.1210/endrev/bnz011
Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation
Abstract
Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is a rare disorder of striking complexity. It arises from somatic, gain-of-function mutations in GNAS, leading to mosaic Gα s activation and inappropriate production of intracellular cyclic adenosine monophosphate (cAMP). The clinical phenotype is largely determined by the location and extent of affected tissues, and the pathophysiological effects of Gα s activation within these tissues. In bone, Gα s activation results in impaired differentiation of skeletal stem cells, leading to discrete skeletal lesions prone to fracture, deformity, and pain. Extraskeletal manifestations include a variable combination of hyperpigmented macules and hyperfunctioning endocrinopathies. Distinctive age-related changes in disease development has key effects on histologic, radiographic, and clinical features. FD/MAS thus presents along a uniquely broad clinical spectrum, and the resulting challenges in diagnosis and management can be difficult for clinicians. This review presents FD/MAS in the context of a mosaic disorder of Gα s activation, providing an intellectual framework within which to understand, evaluate, and treat this interesting disease. It includes a comprehensive summary of current understanding of FD/MAS pathogenesis, and a detailed discussion of clinical presentation and management. Critical areas of unmet need are highlighted, including discussion of key challenges and potential solutions to advance research and clinical care in FD/MAS.
Keywords: fibroblast growth factor 23; growth hormone excess; metabolic bone disease; precocious puberty; skeletal stem cells; somatic mosaicism.
Published by Oxford University Press on behalf of the Endocrine Society 2019.
Figures








Similar articles
-
Brain and eye involvement in McCune-Albright Syndrome: clinical and translational insights.Front Endocrinol (Lausanne). 2023 May 19;14:1092252. doi: 10.3389/fendo.2023.1092252. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37274327 Free PMC article. Review.
-
The Clinical Spectrum of McCune-Albright Syndrome and Its Management.Horm Res Paediatr. 2019;92(6):347-356. doi: 10.1159/000504802. Epub 2019 Dec 19. Horm Res Paediatr. 2019. PMID: 31865341 Free PMC article. Review.
-
Fibrous Dysplasia / McCune-Albright Syndrome.2015 Feb 26 [updated 2024 Feb 8]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2015 Feb 26 [updated 2024 Feb 8]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 25719192 Free Books & Documents. Review.
-
Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives.Curr Osteoporos Rep. 2016 Oct;14(5):178-86. doi: 10.1007/s11914-016-0317-0. Curr Osteoporos Rep. 2016. PMID: 27492469 Free PMC article. Review.
-
Extent of Extraskeletal Manifestations of Fibrous Dysplasia/McCune-Albright Syndrome in Patients with Mazabraud's Syndrome.Calcif Tissue Int. 2022 Mar;110(3):334-340. doi: 10.1007/s00223-021-00918-0. Epub 2021 Dec 2. Calcif Tissue Int. 2022. PMID: 34854944
Cited by
-
Hotspots of Somatic Genetic Variation in Pituitary Neuroendocrine Tumors.Cancers (Basel). 2023 Dec 1;15(23):5685. doi: 10.3390/cancers15235685. Cancers (Basel). 2023. PMID: 38067388 Free PMC article. Review.
-
Zoledronic Acid in a Mouse Model of Human Fibrous Dysplasia: Ineffectiveness on Tissue Pathology, Formation of "Giant Osteoclasts" and Pathogenetic Implications.Calcif Tissue Int. 2020 Dec;107(6):603-610. doi: 10.1007/s00223-020-00752-w. Epub 2020 Sep 1. Calcif Tissue Int. 2020. PMID: 32875378 Free PMC article.
-
Brain and eye involvement in McCune-Albright Syndrome: clinical and translational insights.Front Endocrinol (Lausanne). 2023 May 19;14:1092252. doi: 10.3389/fendo.2023.1092252. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37274327 Free PMC article. Review.
-
Diagnosis, treatment, and management of rickets: a position statement from the Bone and Mineral Metabolism Group of the Italian Society of Pediatric Endocrinology and Diabetology.Front Endocrinol (Lausanne). 2024 Apr 19;15:1383681. doi: 10.3389/fendo.2024.1383681. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38706696 Free PMC article. Review.
-
Burosumab treatment of a child with McCune-Albright syndrome/polyostotic fibrous dysplasia: challenges and benefits.JBMR Plus. 2025 Mar 10;9(5):ziaf042. doi: 10.1093/jbmrpl/ziaf042. eCollection 2025 May. JBMR Plus. 2025. PMID: 40297189 Free PMC article.
References
-
- Boyce AM, Florenzano P, de Castro LF, Collins MT. Fibrous dysplasia/McCune-Albright syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, eds. GeneReviews®. Seattle, WA: University of Washington, Seattle; 1993-2020. - PubMed
-
- Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325(24):1688–1695. - PubMed
-
- Riminucci M, Fisher LW, Majolagbe A, et al. . A novel GNAS1 mutation, R201G, in McCune-Albright syndrome. J Bone Miner Res. 1999;14(11):1987–1989. - PubMed
-
- Idowu BD, Al-Adnani M, O’Donnell P, et al. . A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone. Histopathology. 2007;50(6):691–704. - PubMed